624 results on '"Witzig T"'
Search Results
2. A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma
3. Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients
4. Patterns of Progression on Immune Checkpoint Inhibitor Therapy for Relapsed Hodgkin Lymphoma: Implications for the Potential Role of Radiation Therapy
5. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials
6. P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS
7. P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
8. Detection of B-Cells Clonally Related to the Tumor Population in Multiple Myeloma and MGUS
9. Detection of Peripheral Blood Myeloma Cells by Three-Color Flow Cytometry
10. Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy
11. Anti-CD20 monoclonal antibody-dependent phagocytosis of chronic lymphocytic leukaemia cells by autologous macrophages
12. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma
13. Circulating Peripheral Blood Plasma Cells in Multiple Myeloma
14. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
15. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease
16. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
17. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
18. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy
19. Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma
20. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
21. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma
22. The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling
23. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma
24. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
25. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era
26. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma
27. Incidence of bowel perforation in gastrointestinal lymphomas by location and histology
28. INTERIM PET/CT PREDICTS OUTCOMES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH FRONTLINE LENALIDOMIDE/RCHOP (R2CHOP): LONG‐TERM ANALYSIS OF MC078E
29. IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
30. DO CELL‐OF‐ORIGIN, DOUBLE EXPRESSER, AND DOUBLE HIT STATUS AFFECT OUTCOMES IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (R/R DLBCL)? A PROSPECTIVE OBSERVATIONAL STUDY
31. PROGRESSION‐FREE SURVIVAL AT 24 MONTHS AS A LANDMARK AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
32. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
33. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations
34. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
35. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma
36. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy
37. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy
38. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma
39. Expression of VEGF and its receptors by myeloma cells
40. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma
41. Thalidomide as initial therapy for early-stage myeloma
42. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma
43. Bowel perforation in intestinal lymphoma: incidence and clinical features
44. Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma
45. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma
46. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
47. Proteomic Analysis of Multiple Myeloma Identifies Upregulation of the Novel Protein CRIK: B539
48. MicroRNA Regulate Growth and Angiogenesis in Multiple Myeloma: B581
49. RAD001: Phase II Trial in Relapsed/Refractory Waldenström Macroglobulinemia, the DFCI Experience: A533
50. Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Smoldering or Indolent Myeloma: A481
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.